Does SureTouch work if I have dense breast tissue?
What are calcifications? It says SureTouch can’t detect these?
How is SureTouch different than an ultrasound?
Will my doctor accept this in place of a mammogram?
Is SureTouch covered by insurance?
What are the differences between SureTouch and Breast Thermography? Is one of them more accurate than the other…or better?
How do I know which exam I should get SureTouch or Breast Thermography?
What age can you start getting a SureTouch Breast exam?
How does SureTouch work with Fibrocystic Breast Tissue?
How small of a lump can SureTouch detect?
What is the error % of SureTouch?
Can SureTouch be used as a diagnostic tool?
How does SureTouch compete with other breast exam machines or techniques?
How does SureTouch work with the fibrocystic breast?
Is SureTouch able to identify calcifications?
What about the detection of micro-calcifications or DCIS?
Can I use the hardness levels to benchmark the difference between malignant or benign cancers?
Yes. Breast density is what mammogram measures, but SureTouch measures tissue hardness or elasticity. They are two different properties. If a breast lump is detected, SureTouch uses your breast tissue elasticity as a baseline to compare the hardness.
Calcifications in the breast ducts are detected by mammograms. Otherwise known as DCIS (Ductal Carcinoma In Situ), there has been criticism about over treating these as cancer since 30% of them do not progress into cancer.
The human body has natural mechanisms to correct mutated cells that can turn into cancer, and cancer cells also need the right environment to grow. Proper diet, low in animal protein (less than 10% of caloric consumption), can keep cancer cells from growing. (TC Campbell and TM Campbell, The China Study.)
Ultrasound uses high-frequency sound waves that are sent out into the breast and measure what bounces back. Because it is a narrow beam that provides a crossectional view of the breast, it is difficult to scan the entire breast. Ultrasound is very effective in identifying fluid filled cysts.
A FDA-cleared breakthrough technology, SureTouch is a safe, accurate breast examination that enables all areas of the breast to be examined while offering immediate digitized results for you and your doctor. Originally developed at Harvard, SureTouch measures the increased reactive pressures generated by a questionable breast lesions. The device consists of a hand-held transceiver that is gently moved across the entire breast and underarm area and produces ultra-sensitive, multi-dimensional color images, which are delivered to a screen. With SureTouch, the clinician, patient and doctor can view the size, shape, hardness and location of suspicious masses in real time. Women have the answers they need immediately.
The breast exam that you have is your choice. Your doctor can suggest that you have a mammogram but the decision is yours. We will provide the doctor with all the backup information needed to support SureTouch with your results.
OC Breastwellness can help you submit your claims to your insurance provider.
Breast thermography is a digital infrared picture that reveals the heat and vascular patterns of the breast tissue. These patterns change when a tumor starts to grow. New blood vessels required by the tumor to feed nutrients and oxygen, don’t grow like normal vessels. Their abnormal patters and generated heat is detectable by thermography.
SureTouch is a safe, painless, radiation-free digital breast exam. This breast lesion documentation system utilized tactile sensing technology. The device captures and enhances the sense of touch. Sense of touch accounts for 80% of cancers found today.
A quick free consultation with a member of the staff at OC Breast Wellness is needed to evaluate your unique situation and determine whether one or both of the exams would be appropriate for you.
Just as manual breast exams are not affected by age, SureTouch is effective for younger women as well as older women.
Fibrocystic and glandular tissue can be soft of hard depending on the hormonal cycle. SureTouch determines the hardness of the tissue and compares that with the surrounding tissue. Patients with hard lumpy tissue are asked to come in for a 2nd exam in 2 weeks so that we can isolate lumps due to hormonal changes from a concerning lump. Keep in mind, only 1 out of 12 lumps are cancerous and detecting them early is the key to better outcomes.
While 80 percent of newly diagnosed breast cancers are found by women through their sense of touch during regular self-exams (info), the average size lump found through such self-exam is approximately 2.5cm and the average size lump found by trained medical clinicians using palpation is approximately 1cm. SureTouch is FDA cleared to document palpable lesions and is far more sensitive than human touch and can detect lesions as small as 5mm..
SureTouch displays the breast tissue as it scans over the skin. If a lesion of any size or density is found it is displayed for review. The percentage of palpable lesions undetected would depend on the quality of the nurse performing the exam not on the device itself. If the lesion was under 5mm in size it would not be likely to be detected. Microcalcifications are also not detected by SureTouch.
It is not a diagnostic product. SureTouch is used to visualize the sense of touch, and generate an objective, accurate, and consistent printed report for review by the patient. A second formatted report is for review by the attending medical practitioner, and can be placed in the patient file as needed. A digital report file is also generated and can be appended to the patient’s electronic medical record viewable by mammographers and attending breast surgeons.
SureTouch is not a diagnostic product and therefore is not a competitor. SureTouch enhances clinical breast exams (CBE) by providing a new technology that did not previously exist. Using highly sensitive tactile elasticity imaging, Suretouch electronically documents the CBE in a reproducible format.
The problem with fibrocystic change/mastopathy is that the clinical exam demonstrates a palpable area which is more firm than the surrounding area. Since SureTouch translates the physical exam into a digital image, it will also demonstrate this palpable finding.
In Dr. Kaufman’s paper in AJS, the area of most difficult distinction between cancerous and non-cancerous lesions, was in this group. Again, at this time SureTouch is primarily a documentation device. No SureTouch exam will act as a substitute for a biopsy, as no physical exam (or mammogram/MRI/ultrasound) substitutes for a biopsy.
SureTouch does not identify calcifications, since they are not palpable. All the calcifications associated with cancer are not identified with SureTouch. Occasionally, a fibroadenoma may be calcified, and the fibroadenoma will be identified by SureTouch, simply identifying the palpable lesion, not the fact that it is calcified.
Physical examination does not usually find calcifications. Likewise, SureTouch is not able to identify calcifications. The only calcifications that it may identify are calcified fibroadenomas, or calcified hematomas, etc. In those cases, it is identifying the palpable lesion which happens to be calcified, not the calcifications themselves. Typical calcifications of DCIS are not identified with SureTouch. Only if the DCIS is a mass-forming DCIS does SureTouch have a chance at identifying it. Then again, it is the palpable findings that are being identified.
SureTouch translates the physical exam into a digital reproducible record. Those things that identify the physical exam (shape, size, firmness, consistency) are translated onto the screen. Shape and size are clear. Firmness of an area seen on SureTouch is a measure of the relative firmness of the target lesion relative to the surrounding breast tissue. There are no absolute figures that can be used to diagnose a lesion. Some hard lesions are cancers, cysts, and fibroadenomas. There may also be some softer cancers such as mucinous cancers, although these are still harder than surrounding breast tissue, but not as hard as the prior examples. So, in essence, the hardness measure is a guide as to how different the target lesion is, relative to the normal breast tissue that surrounds it.